What distinguishes AOD-9604 from MK-677?

AOD-9604 is a growth-hormone fragment investigated for obesity. MK-677 is an oral nonpeptide ghrelin-receptor agonist that increases GH and IGF-1.

Has either shown weight-loss benefit?

The large AOD-9604 OPTIONS obesity study did not meet its weight-loss endpoints. An MK-677 older-adult study did not significantly reduce abdominal visceral or total fat; it was not an obesity treatment trial.

Are either FDA approved for weight loss?

Neither has an FDA-approved weight-loss indication in the cited FDA reviews.

Does combining them improve outcomes?

No cited controlled human trial establishes benefit or safety for the combination.

AOD-9604 vs MK-677: Different Evidence

Dossier labels summarize each dossier's research scope. They do not establish comparative treatment benefit or safety. Read the comparison below in that context.

Different studies, different endpoints

AOD-9604 is a modified growth-hormone fragment studied for obesity. MK-677 (ibutamoren) is an oral nonpeptide ghrelin-receptor agonist studied for GH-axis effects and other distinct outcomes. Shared growth-hormone context does not make them interchangeable. FDA AOD-9604 review; FDA ibutamoren review.

Question	AOD-9604	MK-677
Relevant cited population	Adults with obesity in the OPTIONS study	Healthy older adults in a body-composition study
Main finding	Weight-loss endpoints were not met	Fat-free mass increased; abdominal visceral and total fat did not significantly decline
Functional outcome	Not established by the obesity finding	Strength/function did not improve significantly; trial insufficiently powered to rule an effect out
FDA status	No approved weight-loss product identified	No approved ibutamoren product identified

FDA’s AOD-9604 review describes the randomized OPTIONS study: 502 of 536 enrolled adults were randomized. Its weight-loss endpoints at 12 and 24 weeks were not met. This does not establish selective human fat loss or an absence of metabolic risk. FDA AOD-9604 review.

In the 65-person randomized older-adult MK-677 trial, GH, IGF-1 and fat-free mass increased. Abdominal visceral and total fat did not significantly improve; fasting glucose rose and insulin sensitivity fell. Strength/function did not significantly improve, but the study was too small and short to assess those endpoints definitively. It cannot be ranked against the AOD-9604 obesity trial as if both tested the same population or clinical question. Nass et al., PMID 18981485.

Ibutamoren development continues under the LUM-201 name: Phase 3 NCT06948214 was recruiting in the September 29, 2026 official registry archive. This is a pediatric growth-hormone-deficiency program, not a weight-loss approval. FDA ibutamoren review.

No direct trial here supports a ranking, combination or treatment recommendation.

AOD-9604 vs MK-677

AOD-9604

MK-677

Different studies, different endpoints

View Full Dossiers

Stay Updated on Peptide Comparisons